**The FDA's July 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) to recommend BPC-157 for the 503A Bulk Drug Substances List remains the dominant driver of trader positioning.** This non-binding advisory outcome, which went against FDA staff recommendations citing limited human safety and efficacy data, followed the peptide's April 2026 removal from Category 2 restrictions. Full Category 1 placement requires FDA acceptance plus notice-and-comment rulemaking, a process that typically spans eight to twelve months or longer. As of mid-September 2026, no final agency decision or rulemaking has occurred. Market pricing for a December 31, 2026 resolution reflects this extended timeline alongside industry advocacy, telehealth interest, and support from Health Secretary Robert F. Kennedy Jr., tempered by evidentiary gaps and procedural hurdles.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · ZaktualizowanoNOWE
Dec 31, 2026
December 31, 2026
53%
$4,648 Wol.
December 31, 2026
$2,646 Wol.
53%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.**The FDA's July 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) to recommend BPC-157 for the 503A Bulk Drug Substances List remains the dominant driver of trader positioning.** This non-binding advisory outcome, which went against FDA staff recommendations citing limited human safety and efficacy data, followed the peptide's April 2026 removal from Category 2 restrictions. Full Category 1 placement requires FDA acceptance plus notice-and-comment rulemaking, a process that typically spans eight to twelve months or longer. As of mid-September 2026, no final agency decision or rulemaking has occurred. Market pricing for a December 31, 2026 resolution reflects this extended timeline alongside industry advocacy, telehealth interest, and support from Health Secretary Robert F. Kennedy Jr., tempered by evidentiary gaps and procedural hurdles.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Rynek otwarty: Jun 22, 2026, 10:10 PM ET
Wolumen
$4,648Data zakończenia
Jan 1, 2027Rynek otwarty
Jun 22, 2026, 10:10 PM ETRozstrzygający
0x65070be91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.**The FDA's July 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) to recommend BPC-157 for the 503A Bulk Drug Substances List remains the dominant driver of trader positioning.** This non-binding advisory outcome, which went against FDA staff recommendations citing limited human safety and efficacy data, followed the peptide's April 2026 removal from Category 2 restrictions. Full Category 1 placement requires FDA acceptance plus notice-and-comment rulemaking, a process that typically spans eight to twelve months or longer. As of mid-September 2026, no final agency decision or rulemaking has occurred. Market pricing for a December 31, 2026 resolution reflects this extended timeline alongside industry advocacy, telehealth interest, and support from Health Secretary Robert F. Kennedy Jr., tempered by evidentiary gaps and procedural hurdles.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Wolumen
$4,648Data zakończenia
Jan 1, 2027Rynek otwarty
Jun 22, 2026, 10:10 PM ETRozstrzygający
0x65070be91...**The FDA's July 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) to recommend BPC-157 for the 503A Bulk Drug Substances List remains the dominant driver of trader positioning.** This non-binding advisory outcome, which went against FDA staff recommendations citing limited human safety and efficacy data, followed the peptide's April 2026 removal from Category 2 restrictions. Full Category 1 placement requires FDA acceptance plus notice-and-comment rulemaking, a process that typically spans eight to twelve months or longer. As of mid-September 2026, no final agency decision or rulemaking has occurred. Market pricing for a December 31, 2026 resolution reflects this extended timeline alongside industry advocacy, telehealth interest, and support from Health Secretary Robert F. Kennedy Jr., tempered by evidentiary gaps and procedural hurdles.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano
Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania